PATH EX, Inc. has developed CycloPE®, a medical device designed to directly capture and remove bacteria from the bloodstream, providing a rapid, targeted solution for the treatment of sepsis. The company has secured FDA Breakthrough Device Designation and successfully completed preclinical and clinical feasibility studies demonstrating promising clinical outcomes. PATH EX is now advancing toward FDA approval and commercialization.
Fitz Gate invested alongside IAG Capital and the Texas Medical Center Venture Fund in a $5mm round.
